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Abstract: Dendritic cells (DCs) are regarded as the most potent antigen presenting cells that are well suited to activate T cells
toward various antigens, such as tumor-associated antigens, due to their costimulatory activity. There is evidence that DCs are
of diverse origin, with at least two types of myeloid and lymphoid precursors implicated in their generation. The recent reports
demonstrated that the number and function of dendritic cells might change dramatically in cancer patients. In the present study
we evaluated the percentage of myeloid and lymphoid DCs in patients with breast cancer , non-small cell lung cancer (NSCLC)
and in the healthy donors. The percentage of both DC populations was significantly lower in patients with NSCLC than in the
control group. In patients with breast cancer, the number of lymphoid DCs was significantly higher than in NSCLC patients.
The obtained results suggest influence ofpathological states on host immune system. The decrease in the number of DCs in
the peripheral blood from cancer patients may be closely correlated with the type of tumour. 
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Introduction
Dendritic cells (DCs) constitute a family of professional
antigen presenting cells (APC) defined by their morpho-
logy and their unique capacity to generate and regulate
primary immune responses and maintain immunological
memory [2, 7]. The main functions of DCs include the
ability to take up, process and present antigens, to mi-
grate selectively through tissues, and to interact with,
stimulate and direct T- and B-lymphocytes [2, 9]. DCs
represent a system of hematopoietic cells that are rare
but ubiquitously distributed throughout the peripheral
tissues. Their journey starts in the bone marrow where,
at least, two DC lineages have been identified so far,
namely the conventional myeloid-related DCs and the
newly defined lymphoid-related DCs [11, 12]. Both
populations migrate to the blood and become immature
DCs, which wander through tissues where they monitor
the invading pathogens [9, 12]. Upon pathogen capture,
immature DCs receive activation signals, which initiate
their maturation and migration to secondary lymphoid
organs in order to induce antigen-specific immune re-
sponses [9, 12].
In this report we focused on subpopulation of DCs
circulating in peripheral blood. We investigated circu-
lating myeloid- and lymphoid- related DCs using mar-
kers specific for blood dendritic cells: BDCA-1 and
BDCA-2, respectively. BDCA-1 (blood dendritic cell
antigen), which in cluster differentiation corresponds to
CD1c antigen, is expressed on human myeloid subpopu-
lation of peripheral blood dendritic cells (PBDCs),
which are CD4+, CD2+, Lin-, CD123dim and CD45RO+
[2, 7, 9]. BDCA-1-positive cells express myeloid mar-
kers (CD11c+, CD13, CD33), are able to phagocytose
because of the high expression of Fc receptors (CD32,
CD64, FcεRI) and have monocytoid morphology [9,
12]. It is thought that BDCA-1-positive cells express
CD1a and after entering tissues give rise to DCs resem-
bling Langerhans cells and epithelial DCs [12]. BDCA-2
is specifically expressed on human plasmacytoid (lym-
phoid) dendritic cells [3, 4]. This apparently corresponds
to a cell type that previously has been erroneously des-
ignated plasmacytoid T cell or plasmacytoid monocyte
due to its peculiar morphology [4]. BDCA-2-positive
cells are CD4+, Lin-, CD11c- and CD45RA+ [4]. They
express CCR5 (CD195) receptor and CD123 (IL-3Rα),
just as activated lymphocytes, and critically depend on
IL-3 [4, 8]. These cells express neither myeloid lineage
markers (CD13, CD33) nor Fc receptors and show low
phagocytic potential compared to myeloid DCs. The
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main function of lymphoid-related DCs is the secretion
of large amounts of type I interferons upon viral infec-
tion, although they are postulated to enter lymph nodes
through the high endothelial venules and differentiate
into plasmacytoid DCs [2, 4, 12].
During the evolution of pathological condition, the
host immune system is restrained from defence [6, 9].
Tumor cells are poor initiators of immune reaction and
tumor microenviroment can directly inhibit immune
reactivity. It is well established that dendritic cells play
a central role in induction of antitumor immune respon-
ses [5, 6, 10]. The important role of DCs in cancer is
underscored by number of reports in which the presence
of dendritic cells in tumor tissues was associated with
good clinical prognosis of disease [5, 9, 10]. However,
in recent years several groups have described defective
function of DCs in tumor-bearing mice and in cancer
patients [1, 5, 6] . 
These findings call our attention to circulating popu-
lation of dendritic cells. In the present study we assess
quantitatively myeloid- and lymphoid-related DCs in
peripheral blood of patients with non-small cell lung
cancer (NSCLC) and breast cancer. 
Materials and methods
Subjects. The study population consisted of 23 patients with breast
cancer and 13 patients with non-small cell lung cancer (8 male and
5 female). All patients had advanced cancer with no prior che-
miotherapy. 21 healthy age-matched volunteers served as controls.
Informed consent was obtained from each individual. 
Preparation of the mononuclear cells. All peripheral blood sam-
ples were collected in heparinized tubes and immediately processed.
Mononuclear cells were isolated by density gradient centrifugation
on Gradisol L (Aqua Medica, Poland). Interphase cells were
removed, washed twice in PBS without Ca2+ and Mg2+ (Biomed,
Poland) containing 0.5% bovine serum albumin (BSA) and 2 mM
EDTA (Sigma, Germany) and then resuspended in the same buffer
for future immunostaining.
Phenotyping of the cells. Non-specific staining was inhibited by
adding 20 µl of FcR Blocking Reagent to 107 or fewer cells resus-
pended in the buffer prior the labelling. Immunofluorescence studies
were performed using combination of the following monoclonal
antibodies (mAbs): mouse anti-human BDCA-1 FITC (Miltenyi-
Biotec, Germany), mouse anti-human BDCA-2 FITC (Miltenyi-Bio-
tec, Germany), anti-CD123 PE (Becton Dickinson, USA) and
anti-CD19 Cy-Chrome (Pharmingen, USA). The cells were incu-
bated for 10 min in dark at 4˚C and washed in the buffer afterwards.
Flow cytometric analysis. Cells were analysed using a FACSCali-
bur flow cytometer (Becton Dickinson) equipped with 488-nm argon
laser. An acquisition gate was established based on FSC and SSC
that included both the lymphocyte and monocyte populations (mono-
nuclear cells) and excluded dead cells and debris. Each measurement
contained 300 000 total events. After aquisition cells were analysed
with CellQuest software.
Statistical analysis. Statistical analysis was performed using Wil-
coxon-non-parametric test, U Mann-Whitney test and Statistica 5.0
software. 
Results
In our study we defined subpopulation of myeloid den-
dritic cells as BDCA-1-positive and CD19-negative
cells and lymphoid DCs as BDCA-2 and CD123 double
positive cells. The count of DCs was expressed as per-
centage of the peripheral blood mononuclear cells
(PBMC).
In the control group, the total number of myeloid and
lymphoid dendritic cells was 0.402% ± 0.23 and 0.22%
± 0.14, respectively, of peripheral blood mononuclear
cells. The percentage of myeloid DCs was significantly
higher (p<0.01) than that of lymphoid DCs (Figs. 1, 2).
In the group of patients with breast cancer, the per-
centage of myeloid DCs (0.403% ± 0.325 of PBMC) was
significantly higher (p<0.01) than that of lymphoid DCs
(0.23% ± 0.11 of PBMC) (Figs. 1, 2).
In patients with non-small cell lung cancer, the per-
centage of myeloid- and lymphoid-related DCs was
0.253% ± 0.2 and 0.193% ± 0.166 of PBMC, respective-
ly. The percentage of myeloid-related DCs was also
significantly higher (p<0.001) than that of lymphoid
DCs (Figs. 1, 2).
Comparison of dendritic cell subsets between
NSCLC patients and healthy donors demonstrates that
the percentage of both myeloid and lymphoid DCs was
significantly lower (p<0.05) in patients with non-small
cell lung cancer than in the control group (Fig. 3). No
statistically significant differences in the percentage of
myeloid and lymphoid DCs between control groups and
breast cancer patients were found. We also noticed that
in blood from patients with NSCLC, the number of
lymphoid DCs was significantly lower (p<0.05) than in
patients with breast cancer (Fig. 4). 
Discussion
It is clear that in cancer patients, the immune response
to cancer cells has failed [1]. Cancers probably acquire
many characteristics that allow them to evade an effec-
tive immune response [6, 9]. The presence of functional,
competent DCs is critical for effective antitumor control
and for the success of cancer immunotherapy. There is
ample evidence of inadequate function of these cells in
tumor-bearing hosts [1, 6]. Tumor cells may produce
several growth factors and cytokines able to affect he-
matopoiesis, differentiation and accumulation of effec-
tor cells at the site of neoplastic lesion [1, 6].
In our study, we investigated differences in myeloid
and lymphoid DCs circulating in peripheral blood of
cancer patients. We found that in all examined groups
the percentages of myeloid DCs was significantly higher
than that of lymphoid DCs. According to the function of
myeloid DCs we conclude that abundance of myeloid
DCs in cancer patients may correspond to predominance
of Th1 type of immune response what is comparable
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with healthy donors. We found noteworthy unchanged
ratio but decrease in percentage of both populations of
DCs in NSCLC patients. On the contrary, Almand et al.
found increased production of immature myeloid cells
in cancer patients and these cells were able to directly
inhibit antigen-specific T-cell responses [1]. Gabrilo-
vich et al. isolated DCs from the peripheral blood of
patients with breast cancer. They demonstrated signifi-
cantly reduced ability to cluster and to stimulate immune
responses by this population of DCs [5]. We found no
significant differences in both populations of DCs be-
tween breast cancer patients and healthy donors. The
higher percentage of lymphoid DCs in breast cancer
patients compared to NSCLC patients may result from
different sex of the examined subjects [14]. The level of
estrogens, predominant hormones in females, corre-
sponds to higher levels of lymphoid DCs [13]. 
There is now enough evidence that defective DC
function is an important mechanism of tumor escape
from the immune system control [6]. Our observation
presented in this paper is a pilot study on the quantitative
analysis of dendritic cells and allows us to conclude that
the amount of DCs in peripheral blood of cancer patients
may correspond to the type of neoplasm. It faces us with
the necessity to expand the examined groups and to
include the other pathological conditions. The further
study should be aimed at comparisons of the stage,
duration and localization of neoplasm with the number
of dendritic cells. 
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